Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
19.39
+1.55 (8.69%)
May 20, 2026, 3:33 PM EDT - Market open
Zenas BioPharma Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Zenas BioPharma stock has a consensus rating of "Strong Buy" and an average price target of $42.13. The average 1-year stock price forecast is 117.28% higher than the current stock price, while the lowest is $22 (+13.46%) and the highest is $55 (+183.65%).
Price Target: $42.13 (+117.28%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Zenas BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 5 | 4 | 3 | 3 | 3 | 3 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $44 | Strong Buy | Reiterates | $44 | +126.92% | May 15, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $21 → $22 | Hold | Maintains | $21 → $22 | +13.46% | May 14, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $43 → $41 | Strong Buy | Maintains | $43 → $41 | +111.45% | Mar 17, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $45 → $55 | Strong Buy | Maintains | $45 → $55 | +183.65% | Mar 17, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $19 → $21 | Hold | Maintains | $19 → $21 | +8.30% | Mar 17, 2026 |
Financial Forecast
Revenue This Year
18.08M
from 10.00M
Increased by 80.83%
Revenue Next Year
62.16M
from 18.08M
Increased by 243.72%
EPS This Year
-4.93
from -8.44
EPS Next Year
-5.15
from -4.93
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 74.5M | 86.1M | ||||||
| Avg | 18.1M | 62.2M | ||||||
| Low | n/a | 22.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 644.6% | 376.1% | ||||||
| Avg | 80.8% | 243.7% | ||||||
| Low | - | 25.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -4.61 | -4.56 | |||
| Avg | -4.93 | -5.15 | |||
| Low | -5.92 | -5.71 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.